Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988. Here we review the evidence implicating ET-1 in tumorigenesis. In particular, we concentrate on the role of ET-1 ...

The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

Increased endogenous endothelin activity contributes to vascular dysfunction in obesity and diabetes. We report augmented effects of BQ123, an antagonist of type A endothelin receptors, to reduce ...

TRYVIO (aprocitentan) is an endothelin receptor antagonist that inhibits the binding of endothelin (ET)-1 to ETA and ETBreceptors.1,2The effects of ET-1 bear many similarities with the ...

Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.

There is increasing evidence that endothelin-1 has a pathogenic role in pulmonary arterial hypertension 10 and that blockade of endothelin receptors may be beneficial. 11 Endothelin-1 is a potent ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

Endothelin (ET) is a recently discovered 21-amino acid peptide that has potent physiologic and pathophysiologic effects that appear to be involved in the development of heart failure. These ...

SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2 ...

According to Briyal and her mentor Anil Gulati, PhD, this is the first report to indicate that selective stimulation of the endothelin B receptors by IV injection of IRL-1620 improves memory, reduces ...

PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at low and high doses and compared with control, showing structure improvements in macular ischemia, leakage and microaneurysms.